Daina Graybosch
Stock Analyst at Leerink Partners
(0.08)
# 4,481
Out of 4,534 analysts
496
Total ratings
38.8%
Success rate
-7.9%
Average return
Main Sectors:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Downgraded: Hold | $129 → $127 | $133.21 | -4.66% | 29 | Jul 20, 2026 | |
| CGEN Compugen | Maintained: Buy | $13 → $5 | $2.34 | +113.68% | 28 | May 21, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $49 → $47 | $28.22 | +66.55% | 25 | Apr 20, 2026 | |
| BNTX BioNTech SE | Downgraded: Hold | $107 → $113 | $92.16 | +22.61% | 67 | Feb 2, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $107 → $114 | $124.40 | -8.36% | 77 | Dec 15, 2025 | |
| IPSC Century Therapeutics | Downgraded: Hold | $7 → $2 | $2.21 | -9.30% | 26 | Nov 17, 2025 | |
| SMMT Summit Therapeutics | Maintained: Sell | n/a | $13.50 | - | 7 | Oct 22, 2025 | |
| NBP NovaBridge Biosciences | Initiated Coverage: Buy | $9 | $1.79 | +404.20% | 1 | Oct 6, 2025 | |
| IPHA Innate Pharma | Downgraded: Hold | $2 | $1.73 | +15.61% | 32 | Sep 18, 2025 | |
| FATE Fate Therapeutics | Maintained: Buy | $12 → $7 | $2.80 | +150.45% | 37 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $6 | $4.48 | +34.08% | 21 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $10 | $0.368 | +2,617.39% | 20 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $8.57 | +226.72% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.57 | +211.28% | 20 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.64 | +92.31% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $0.39 | $0.000001 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $4.04 | n/a | 19 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $67.70 | n/a | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $64.84 | n/a | 26 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.48 | n/a | 1 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.0001 | n/a | 10 | Apr 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $1.8 | $6.44 | n/a | 8 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 35.00 | CHF 3.17 | n/a | 1 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €83.04 → €87.41 | €134.95 | n/a | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $47.49 | n/a | 1 | May 22, 2019 |
Gilead Sciences
Jul 20, 2026
Downgraded: Hold
Price Target: $129 → $127
Current: $133.21
Upside: -4.66%
Compugen
May 21, 2026
Maintained: Buy
Price Target: $13 → $5
Current: $2.34
Upside: +113.68%
Arcus Biosciences
Apr 20, 2026
Maintained: Buy
Price Target: $49 → $47
Current: $28.22
Upside: +66.55%
BioNTech SE
Feb 2, 2026
Downgraded: Hold
Price Target: $107 → $113
Current: $92.16
Upside: +22.61%
Merck & Co.
Dec 15, 2025
Maintained: Buy
Price Target: $107 → $114
Current: $124.40
Upside: -8.36%
Century Therapeutics
Nov 17, 2025
Downgraded: Hold
Price Target: $7 → $2
Current: $2.21
Upside: -9.30%
Summit Therapeutics
Oct 22, 2025
Maintained: Sell
Price Target: n/a
Current: $13.50
Upside: -
NovaBridge Biosciences
Oct 6, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $1.79
Upside: +404.20%
Innate Pharma
Sep 18, 2025
Downgraded: Hold
Price Target: $2
Current: $1.73
Upside: +15.61%
Fate Therapeutics
Sep 4, 2025
Maintained: Buy
Price Target: $12 → $7
Current: $2.80
Upside: +150.45%
Sep 4, 2025
Maintained: Hold
Price Target: $20 → $6
Current: $4.48
Upside: +34.08%
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $10
Current: $0.368
Upside: +2,617.39%
Aug 15, 2025
Reiterated: Buy
Price Target: $28
Current: $8.57
Upside: +226.72%
Aug 13, 2025
Maintained: Buy
Price Target: $8
Current: $2.57
Upside: +211.28%
Aug 13, 2025
Reiterated: Buy
Price Target: $7
Current: $3.64
Upside: +92.31%
May 14, 2025
Downgraded: Hold
Price Target: $5 → $0.39
Current: $0.000001
Upside: n/a
Aug 28, 2024
Maintained: Hold
Price Target: $6
Current: $4.04
Upside: n/a
Dec 11, 2023
Maintained: Buy
Price Target: n/a
Current: $67.70
Upside: n/a
Sep 15, 2023
Maintained: Hold
Price Target: $1.5
Current: $64.84
Upside: n/a
Jun 5, 2023
Maintained: Buy
Price Target: n/a
Current: $4.48
Upside: n/a
Apr 27, 2022
Maintained: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Apr 1, 2022
Downgraded: Hold
Price Target: $25 → $1.8
Current: $6.44
Upside: n/a
Apr 6, 2021
Maintained: Buy
Price Target: CHF 35.00
Current: CHF 3.17
Upside: n/a
Aug 25, 2020
Maintained: Buy
Price Target: €83.04 → €87.41
Current: €134.95
Upside: n/a
May 22, 2019
Maintained: Hold
Price Target: $5
Current: $47.49
Upside: n/a